Stepping Up the Game: Measles, Mumps, Rubella and Varicella (MMRV) Concomitant Testing Support for Vaccine Evaluation

The introduction of vaccines against Measles, Mumps, Rubella (MMR), and Varicella (the “V” in MMRV vaccines) led to a drop in the incidence of these diseases by 89% (Varicella) and 99% (MMR). These effective vaccines are a core component in most pediatric immunization programs across the world. Hence, every time a new pediatric vaccine is added to the existing immunization schedule, clinical evidence must be provided that the newcomer does not adversely influence the immunogenic response to the MMRV-licensed vaccines. These required non-inferiority studies when vaccines are co-administered (known as concomitant vaccine testing) come with their own challenges.

Continue reading

Novel Assays Support RSV Drug and Vaccine Development

Chances are you’ve been hit by the respiratory syncytial virus (RSV), which infects nearly everyone by the age of 2 and usually reinfects exposed people throughout their lifetimes. While most healthy people experience mild to moderate cold-like symptoms, RSV Drug and Vaccine DevelopmentRSV can also cause severe infections. It has earned notoriety as the leading cause of hospital stays for newborns, and RSV-associated infections in infants cause up to 200,000 deaths per year worldwide in developed countries.

With only limited, supportive treatments to help patients with RSV, scientists at Monogram Biosciences, Inc. (part of the LabCorp Specialty Testing Group) recently examined ways to help sponsors develop an RSV vaccine or antiviral medication that can treat or even prevent this illness. Continue reading

Behind the Scenes with Kits & Logistics for Vaccine Studies

Whether large or small, vaccine studies differ from standard drug development in many Kits & Logistics for Vaccine Studies ways. Sarah Slette, Sr. Study Manager, Vaccines & Novel Immunotherapeutics at Covance, explains the unique challenges her team faces and their solutions to rapidly deliver customized vaccine kits to sponsors’ sites across the globe.

Continue reading

Vaccines and Immunotherapeutics: Three Ways to Improve Your Chances of Success

Advancing vaccine and novel immunotherapeutic development requires focused, specialized expertise. If you are looking to reveal more efficiencies in your vaccine and novel immunotherapeutic testing strategy, consider these three beVaccines and Immunotherapeutics: Three ways to improve your chances of successst practices:

1. Apply resources specifically tailored to your development

As you advance your vaccine or novel immunotherapeutic, it’s crucial to match solutions to your needs so you make the most of your efforts. Our dedicated vaccine and novel immunotherapeutic experts offer a consultative approach to determine exactly how to meet your requirements and accelerate your program. Co-located under the same roof, our scientists and study managers assign you a single point of contact to help simplify communications and decision-making so you can concentrate on the next steps. Continue reading

Vaccine and Novel Immunotherapeutic Development: A Personal Quest

Like my colleagues at Covance, my work ultimately contributes to improving Vaccine and Novel Immunotherapeutic Development Covance Bloghealthcare and patients’ lives. Our efforts to accelerate fresh approaches towards effective treatments became deeply personal in 2007 when my oldest sister, Vicki, was diagnosed with advanced Triple Negative Breast Cancer (TNBC).

From her initial diagnosis, my sister was full of vitality and enjoyed a high quality of life due in part to several of the novel treatments that Covance had helped develop. She even participated in a long-term clinical trial involving an angiogenesis-inhibitor, in addition to traditional chemotherapy, during her early treatment.

Vicki became a student of her diagnosis, reading countless journal articles on the rapid advances in scientific understanding. When her health took a sharp decline, she asked for my support in helping her gain access to a new trial focused on the immune system. She wanted to do whatever she could to help others find a better treatment, or even a cure, for TNBC. Ultimately, she was too weak to make the journey to participate in a cutting-edge clinical trial. Vicki died on October 1st, 2013.

Continue reading

Five Key Advances in Infectious Disease Drug Development

Infectious diseases contribute to approximately 25%Advances in Infectious Disease Drug and Vaccine Development Covance Blog of global mortality and present critical healthcare challenges, especially in under-resourced countries. Recent research and development breakthroughs may help transform this situation. The industry is now leveraging novel analytical and bioinformatics technologies to better understand the biology and response to viral and bacteriological infections, and thereby develop more rapid and effective strategies for evaluating new therapeutic agents in clinical trials.

1. Applying lessons learned

Hepatitis C virus (HCV) therapeutics, frequently described as a breakthrough area in drug development, because it highlights the result of combining the biological understanding of disease and prioritizing appropriate resources to speed drug development. The first curative therapeutic regimens containing direct-acting agents for this important cause of liver disease were approved in 2011. Since then, seven additional regimens have received FDA approval with several more promising treatments currently in late stage clinical trials. Continue reading